On the pathophysiology and treatment of akinetic mutism

Neurosci Biobehav Rev. 2020 May:112:270-278. doi: 10.1016/j.neubiorev.2020.02.006. Epub 2020 Feb 7.

Abstract

Akinetic mutism (AM) is a rare neurological disorder characterized by the presence of an intact level of consciousness and sensorimotor capacity, but with a simultaneous decrease in goal-directed behavior and emotions. Patients are in a wakeful state of profound apathy, seemingly indifferent to pain, thirst, or hunger. It represents the far end within the spectrum of disorders of diminished motivation. In recent years, more has become known about the functional roles of neurocircuits and neurotransmitters associated with human motivational behavior. More specific, there is an increasing body of behavioral evidence that links specific damage of functional frontal-subcortical organization to the occurrence of distinct neurological deficits. In this review, we combine evidence from lesion studies and neurophysiological evidence in animals, imaging studies in humans, and clinical investigations in patients with AM to form an integrative theory of its pathophysiology. Moreover, the specific pharmacological interventions that have been used to treat AM and their rationales are reviewed, providing a comprehensive overview for use in clinical practice.

Keywords: Akinetic mutism; Behavior; Disorders of diminished motivation; Frontal-subcortical neurocircuitry.

Publication types

  • Review

MeSH terms

  • Adrenergic Uptake Inhibitors / therapeutic use*
  • Akinetic Mutism* / drug therapy
  • Akinetic Mutism* / pathology
  • Akinetic Mutism* / physiopathology
  • Animals
  • Dopamine Agonists / therapeutic use*
  • Dopamine Uptake Inhibitors / therapeutic use*
  • Dopaminergic Neurons* / drug effects
  • Dopaminergic Neurons* / pathology
  • Dopaminergic Neurons* / physiology
  • GABA-A Receptor Agonists / therapeutic use*
  • Gray Matter* / drug effects
  • Gray Matter* / pathology
  • Gray Matter* / physiopathology
  • Humans
  • Motivation* / drug effects
  • Motivation* / physiology
  • Zolpidem / therapeutic use*

Substances

  • Adrenergic Uptake Inhibitors
  • Dopamine Agonists
  • Dopamine Uptake Inhibitors
  • GABA-A Receptor Agonists
  • Zolpidem